AAV-based galactosidase beta 1 gene therapy (JCR/Jikei University/Juntendo University)

N/A

Report date: 2025/01/26 15:58:24

Base Information

Drug NameAAV-based galactosidase beta 1 gene therapy (JCR/Jikei University/Juntendo University)

Drug Alias NameAAV anti-TfR:GB1 gene therapy (JCR/Jikei University/Juntendo University)GB1 gene therapy (JCR/Jikei University/Juntendo University)galactosidase beta 1 gene therapy (JCR/Jikei University/Juntendo University)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionBeta-galactosidase stimulantsTransferrin receptors modulators

TargetsBeta-galactosidaseTransferrin receptors

Therapy Area/IndicationsGangliosidosis, GM1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJcr Pharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJcr Pharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsGangliosidosis, GM1

Inactive IndicationsN/A

Other Information

ATC CodeN/A